Cerebrospinal Fluid MicroRNA Signatures as Diagnostic
Biomarkers in Brain Tumors

J 2019

Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors

KOPKOVÁ, Alena, Jiří ŠÁNA, Táňa MACHÁČKOVÁ, Marek VEČEŘA, Lenka RADOVÁ et. al.

Základní údaje

Originální název

Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors

Autoři

KOPKOVÁ, Alena (203 Česká republika, domácí), Jiří ŠÁNA (203 Česká republika, domácí), Táňa MACHÁČKOVÁ (203 Česká republika, domácí), Marek VEČEŘA (703 Slovensko, domácí), Lenka RADOVÁ (203 Česká republika, domácí), Karolína TRACHTOVÁ (203 Česká republika, domácí), Václav VYBÍHAL (203 Česká republika, domácí), Martin SMRČKA (203 Česká republika, domácí), Tomáš KAZDA (203 Česká republika, domácí), Ondřej SLABÝ (203 Česká republika, domácí) a Pavel FADRUS (203 Česká republika, garant, domácí)

Vydání

Cancers, BASEL, MDPI, 2019, 2072-6694

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.126

Kód RIV

RIV/00216224:14740/19:00108555

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.3390/cancers11101546

UT WoS

000498826000143

Klíčová slova anglicky

glioblastoma; meningioma; brain metastases; microRNA; cerebrospinal fluid

Štítky

14110224, 14110812, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 26. 2. 2020 12:13, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Central nervous system (CNS) malignancies include primary tumors that originate within the CNS as well as secondary tumors that develop as a result of metastatic spread. Circulating microRNAs (miRNAs) were found in almost all human body fluids including cerebrospinal fluid (CSF), and they seem to be highly stable and resistant to even extreme conditions. The overall aim of our study was to identify specific CSF miRNA patterns that could differentiate among brain tumors. These new biomarkers could potentially aid borderline or uncertain imaging results onto diagnosis of CNS malignancies, avoiding most invasive procedures such as stereotactic biopsy or biopsy. In total, 175 brain tumor patients (glioblastomas, low-grade gliomas, meningiomas and brain metastases), and 40 non-tumor patients with hydrocephalus as controls were included in this prospective monocentric study. Firstly, we performed high-throughput miRNA profiling (Illumina small RNA sequencing) on a discovery cohort of 70 patients and 19 controls and identified specific miRNA signatures of all brain tumor types tested. Secondly, validation of 9 candidate miRNAs was carried out on an independent cohort of 105 brain tumor patients and 21 controls using qRT-PCR. Based on the successful results of validation and various combination patterns of only 5 miRNA levels (miR-30e, miR-140, let-7b, mR-10a and miR-21-3p) we proposed CSF-diagnostic scores for each tumor type which enabled to distinguish them from healthy donors and other tumor types tested. In addition to this primary diagnostic tool, we described the prognostic potential of the combination of miR-10b and miR-196b levels in CSF of glioblastoma patients. In conclusion, we performed the largest study so far focused on CSF miRNA profiling in patients with brain tumors, and we believe that this new class of biomarkers have a strong potential as a diagnostic and prognostic tool in these patients.

Návaznosti

NV15-34553A, projekt VaV

Název: Využití mikroRNA v mozkomíšním moku pro diagnostiku mozkových nádorů

Citovat

KOPKOVÁ, Alena, Jiří ŠÁNA, Táňa MACHÁČKOVÁ, Marek VEČEŘA, Lenka RADOVÁ, Karolína TRACHTOVÁ, Václav VYBÍHAL, Martin SMRČKA, Tomáš KAZDA, Ondřej SLABÝ a Pavel FADRUS. Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors. Cancers. BASEL: MDPI, 2019, roč. 11, č. 10, s. 1-12. ISSN 2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers11101546.

@article{1597463,
   author = {Kopková, Alena and Šána, Jiří and Macháčková, Táňa and Večeřa, Marek and Radová, Lenka and Trachtová, Karolína and Vybíhal, Václav and Smrčka, Martin and Kazda, Tomáš and Slabý, Ondřej and Fadrus, Pavel},
   article_location = {BASEL},
   article_number = {10},
   doi = {http://dx.doi.org/10.3390/cancers11101546},
   keywords = {glioblastoma; meningioma; brain metastases; microRNA; cerebrospinal fluid},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors},
   url = {https://www.mdpi.com/2072-6694/11/10/1546},
   volume = {11},
   year = {2019}
}

TY  - JOUR
ID  - 1597463
AU  - Kopková, Alena - Šána, Jiří - Macháčková, Táňa - Večeřa, Marek - Radová, Lenka - Trachtová, Karolína - Vybíhal, Václav - Smrčka, Martin - Kazda, Tomáš - Slabý, Ondřej - Fadrus, Pavel
PY  - 2019
TI  - Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors
JF  - Cancers
VL  - 11
IS  - 10
SP  - 1-12
EP  - 1-12
PB  - MDPI
SN  - 20726694
KW  - glioblastoma
KW  - meningioma
KW  - brain metastases
KW  - microRNA
KW  - cerebrospinal fluid
UR  - https://www.mdpi.com/2072-6694/11/10/1546
L2  - https://www.mdpi.com/2072-6694/11/10/1546
N2  - Central nervous system (CNS) malignancies include primary tumors that originate within the CNS as well as secondary tumors that develop as a result of metastatic spread. Circulating microRNAs (miRNAs) were found in almost all human body fluids including cerebrospinal fluid (CSF), and they seem to be highly stable and resistant to even extreme conditions. The overall aim of our study was to identify specific CSF miRNA patterns that could differentiate among brain tumors. These new biomarkers could potentially aid borderline or uncertain imaging results onto diagnosis of CNS malignancies, avoiding most invasive procedures such as stereotactic biopsy or biopsy. In total, 175 brain tumor patients (glioblastomas, low-grade gliomas, meningiomas and brain metastases), and 40 non-tumor patients with hydrocephalus as controls were included in this prospective monocentric study. Firstly, we performed high-throughput miRNA profiling (Illumina small RNA sequencing) on a discovery cohort of 70 patients and 19 controls and identified specific miRNA signatures of all brain tumor types tested. Secondly, validation of 9 candidate miRNAs was carried out on an independent cohort of 105 brain tumor patients and 21 controls using qRT-PCR. Based on the successful results of validation and various combination patterns of only 5 miRNA levels (miR-30e, miR-140, let-7b, mR-10a and miR-21-3p) we proposed CSF-diagnostic scores for each tumor type which enabled to distinguish them from healthy donors and other tumor types tested. In addition to this primary diagnostic tool, we described the prognostic potential of the combination of miR-10b and miR-196b levels in CSF of glioblastoma patients. In conclusion, we performed the largest study so far focused on CSF miRNA profiling in patients with brain tumors, and we believe that this new class of biomarkers have a strong potential as a diagnostic and prognostic tool in these patients.
ER  -

KOPKOVÁ, Alena, Jiří ŠÁNA, Táňa MACHÁČKOVÁ, Marek VEČEŘA, Lenka RADOVÁ, Karolína TRACHTOVÁ, Václav VYBÍHAL, Martin SMRČKA, Tomáš KAZDA, Ondřej SLABÝ a Pavel FADRUS. Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors. \textit{Cancers}. BASEL: MDPI, 2019, roč.~11, č.~10, s.~1-12. ISSN~2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers11101546.

Podrobný výpis o publikaci